Patent ID: 11970711
Assignee: UNIVERSITY OF VIENNA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  H  Y | IPC A  C  H

Claim 25:
26. A kit comprising
(a) a chimeric Cas9 protein or a nucleic acid encoding the chimeric Cas9 protein, wherein the chimeric Cas9 protein comprises a Cas9 polypeptide fused to a heterologous polypeptide that has DNA-modifying deamination activity, wherein the Cas9 polypeptide is a Streptococcus pyogenes Cas9 with one or more mutations in a RuvC domain and/or an HNH domain; and
(b) a DNA-targeting RNA or one or more nucleic acids encoding the DNA-targeting RNA, wherein the DNA-targeting RNA comprises:
(i) a targeter-RNA comprising: (1) a first nucleotide sequence that is complementary to a target sequence of a target DNA, and (2) a second nucleotide sequence that hybridizes with an activator-RNA; and
(ii) the activator-RNA, which hybridizes with the targeter-RNA to form a double-stranded RNA duplex, wherein the activator-RNA hybridizes with the targeter-RNA to form a total of 8 to 15 base pairs,, wherein the DNA-targeting RNA is capable of forming a complex with the chimeric Cas9 protein and guiding the complex to the target sequence, and
wherein (a) and (b) are separated.